Last reviewed · How we verify
LN-145
At a glance
| Generic name | LN-145 |
|---|---|
| Also known as | Autologous Tumor Infiltrating Lymphocytes, TIL, autologous tumor infiltrating lymphocytes, TIL, Autologous Tumor Infiltrating Lymphocytes |
| Sponsor | Karam Khaddour, MD, MS |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TIL Therapy in cSCC and MCC (PHASE2)
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma (PHASE1)
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (PHASE2)
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer (PHASE2)
- Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma (PHASE2)
- Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants (PHASE1)
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (PHASE2)
- Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LN-145 CI brief — competitive landscape report
- LN-145 updates RSS · CI watch RSS
- Karam Khaddour, MD, MS portfolio CI